Janus Henderson Group PLC Arcutis Biotherapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $188 Billion
- Q4 2024
A detailed history of Janus Henderson Group PLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 52,600 shares of ARQT stock, worth $672,228. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,600
Previous 52,600
-0.0%
Holding current value
$672,228
Previous $489,000
49.69%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
213Shares Held
130MCall Options Held
2.07MPut Options Held
151K-
Jennison Associates LLC12.3MShares$158 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$146 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$140 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$112 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$110 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $769M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...